Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK transaction
Exclusively intended for persons who are not residents of the United States and who are not physically present in the United States.
-
GSK transaction launch
Exclusively intended for persons who are not residents of the United States and who are not physically present in the United States
-
GSK announces major new commitment to Asia
GlaxoSmithKline (GSK) is strengthening its presence in Singapore by establishing a new global headquarters for Asia
-
GSK completes major three-part transaction with Novartis
GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion
-
GlaxoSmithKline plc announces changes to its Board
GSK today announces that Sir Christopher Gent will step down as Chairman of GSK at the Company’s Annual General Meeting on 7 May 2015
-
Update on three-part transaction with Novartis
GSK today announces good progress on obtaining clearances and approvals to enable completion of its three-part transaction with Novartis
-
GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
GSK today announced that it has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland.
-
GSK and Theravance announce start of phase III lung function study with ‘closed’ triple combination treatment FF/UMEC/VI for COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a second global phase III study
-
GSK announces positive overall survival results from phase III COMBI-d study of dabrafenib (Tafinlar™) and trametinib (Mekinist™) combination
GSK today announced overall survival results from COMBI-d which demonstrate a statistically significant reduction in the risk of death
-
GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™)
GSK today announced the submission to the European Medicines Agency of a variation to the Marketing Authorisation for eltrombopag (Revolade)
-
Results announcement for the fourth quarter 2014
GSK delivers 2014 core EPS of 95.4p (-1% CER excluding divestments) and dividend of 80 pence per share (+3%)
-
Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
Organisations from South Africa, Zambia, Kenya and Uganda and Save the Children for innovations proven to help reduce deaths in under-fives
-
Regulatory update on three-part transaction with Novartis
GlaxoSmithKline plc (GSK) has today received clearance from the European Commission of its proposed three-part transaction with Novartis
-
GSK statement on Oxford University phase I trial results of an Ebola candidate vaccine
Results from a phase I trial published by Oxford University show that a GSK/NIH Ebola vaccine demonstrated an acceptable safety profile
-
Board Committee change
GSK announces that Sir Philip Hampton has been appointed Chairman of the Nominations Committee (the “Committee”) with effect from today
-
GSK extends its price-freeze commitment to ten years for countries graduating from Gavi support
New extended price freeze enables countries that graduate from Gavi support to continue to pay the same discounted price for GSK vaccines
-
Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial
Healthcare workers among those to be vaccinated in large-scale trial involving up to 30,000 people due to start in the coming weeks
-
GSK ‘confronts COPD’ to deliver new insights from across the globe to promote improved management of chronic lung disease
Data published today suggests, that long-term health outlook for patients with chronic obstructive pulmonary disease (COPD) has improved.
-
GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta™)
GSK announced the submission of sNDA to the US Food and Drug Administration for eltrombopag (Promacta™)
-
Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
GSK announced a phase III study to assess the efficacy of HZ/su, investigational vaccine for shingles, has met its primary endpoint.
